Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Micrus Endovascular and Chemence Medical Products have signed an exclusive agreement to jointly develop liquid embolic products for neurovascular indications using Chemence's cyanoacrylate technology, development capabilities and intellectual property.
Subscribe to our email newsletter
Micrus will be responsible for overseeing the regulatory and clinical process and will be the exclusive worldwide distributor for neurovascular products developed based on this collaborative agreement. Under the terms of the agreement, Micrus has made an upfront payment to Chemence and will make additional payments upon achieving certain development milestones.
John Kilcoyne, chairman and CEO of Micrus, said: “We see significant potential for a liquid embolic to be used either in conjunction with embolic coils or by itself for the treatment of aneurysms. The unique properties of Chemence’s cyanoacrylate technologies may prove capable of providing complete occlusion and treatment of cerebral aneurysms within a matter of minutes.”